Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein N-terminal asparagine amidase (NTAN1) is an enzyme that catalyzes the conversion (deamidation) of N-terminal asparagine residues to aspartate on substrate proteins, a key step in the eukaryotic N-end rule pathway of targeted protein degradation. NTAN1 exhibits high specificity for N-terminal Asn, preferring substrates with hydrophobic second-position residues, and functions via a CNF1/YfiH-like cysteine hydrolase fold with a conserved catalytic triad. Once deamidated, the N-terminal aspartate undergoes arginylation and subsequent ubiquitin-dependent proteasomal degradation. NTAN1 activity is implicated in maintenance of cellular protein turnover and normal neurological function, with genetic variants associated with certain diseases. There are currently no known drugs targeting NTAN1 directly[1][2][3][5].
(For hypothetical drugs): Inhibition or modulation of NTAN1 would block the deamidation of N-terminal Asn, potentially altering protein stability and turnover via the N-end rule pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein N-terminal asparagine amidase (NTAN1).